Literature DB >> 2668563

Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin.

D Liebowitz1, E Kieff.   

Abstract

The latent membrane protein (LMP) of Epstein-Barr virus (EBV) forms patches associated with the vimentin intermediate filament system in EBV-transformed lymphoblastoid cell lines, EBV-infected Burkitt's lymphoma cells, and LMP-transfected, EBV-negative Burkitt's lymphoma cells. By gene transfer, LMP induces the expression of vimentin and B-cell activation antigens in EBV-negative Burkitt's lymphoma cells. We have now expressed LMP in an EBV-positive Burkitt's lymphoma cell line, Daudi, which does not express any LMP or vimentin. In these Daudi transfectants, LMP still formed plasma membrane patches in the absence of vimentin. LMP did not resist nonionic detergent extraction in Daudi cells as it does in vimentin-expressing cells. LMP still retained functional activity as judged by induction of B-cell activation antigens. These data indicate that LMP can form plasma membrane patches and induce B-lymphocyte activation independent of vimentin association.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668563      PMCID: PMC251005     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity.

Authors:  D Wang; D Liebowitz; F Wang; C Gregory; A Rickinson; R Larson; T Springer; E Kieff
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

Review 2.  Epstein-Barr virus infection and immunoregulation in man.

Authors:  G Tosato; R M Blaese
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

3.  Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus.

Authors:  D Liebowitz; D Wang; E Kieff
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

4.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

Authors:  D Wang; D Liebowitz; E Kieff
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

5.  EBV-activation of human B-lymphocytes.

Authors:  P Aman; N Lewin; M Nordström; G Klein
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

6.  Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth.

Authors:  J Gordon; L Walker; G Guy; G Brown; M Rowe; A Rickinson
Journal:  Immunology       Date:  1986-08       Impact factor: 7.397

7.  Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus.

Authors:  C Kintner; B Sugden
Journal:  Nature       Date:  1981-12-03       Impact factor: 49.962

8.  Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma.

Authors:  M Rowe; C M Rooney; C F Edwards; G M Lenoir; A B Rickinson
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

9.  Early events in Epstein-Barr virus infection provide a model for B cell activation.

Authors:  D A Thorley-Lawson; K P Mann
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Vimentin gene: expression in human lymphocytes and in Burkitt's lymphoma cells.

Authors:  A Lilienbaum; V Legagneux; M M Portier; K Dellagi; D Paulin
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  17 in total

1.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.

Authors:  R Longnecker; C L Miller; X Q Miao; A Marchini; E Kieff
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.

Authors:  A L Burkhardt; J B Bolen; E Kieff; R Longnecker
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant.

Authors:  A Marchini; J I Cohen; F Wang; E Kieff
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.

Authors:  R Longnecker; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression.

Authors:  W E Miller; J L Cheshire; N Raab-Traub
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

8.  Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors.

Authors:  M Higuchi; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

9.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  Induction of epidermal growth factor receptor expression by Epstein-Barr virus latent membrane protein 1 C-terminal-activating region 1 is mediated by NF-kappaB p50 homodimer/Bcl-3 complexes.

Authors:  Natalie J Thornburg; Nancy Raab-Traub
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.